
News|Articles|September 29, 2026
PBM Satisfaction Stalls as Net Promoter Score Turns Negative
Author(s)Maggie L. Shaw
Fact checked by: Giuliana Grossi
The NPS index, ranging from –100 to +100, serves as a proxy for customers’ willingness to recommend products and services they themselves have used.
Advertisement
Advertisement
Employer and health plan satisfaction with pharmacy benefits managers (PBMs) has plateaued near its lowest point in a decade, while a separate loyalty measure shows a more striking change: Net Promoter Score (NPS) for PBMs has swung from +18 in 2022 to –13 in 2026. These findings come from the new Pharmacy Benefit Manager Customer Satisfaction Report published online today,1 which surveyed 250 benefits leaders about their willingness to recommend a product or service they themselves have used.2
Related to this article

AHIP's Jeanette Thornton explains where 2027 prior authorization standards fit in the affordability debate and what plans want from Congress.

In this Q&A, Rob Stransky of NiceRx explains how to screen patients for gray-market retatrutide use and why cost drives demand for unregulated peptides.

This week in health equity and access: Medicaid cuts; mailed FIT outreach; EEOC pregnancy rules; GLP-1 Bridge access; and 2027 policy shifts.

Cancer care demand is constantly shifting, with panelists at PCOC 2026 debating the benefits of automation vs retaining live patient access.

A prospective Italian study of 492 postmenopausal women found ultrasound signs of deep endometriosis in 7.3%, often plaque-like and poorly vascularized.

A new tool puts this year's measles toll at nearly $83 million as global health experts weigh whether the US has lost elimination status.

The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
Advertisement
Advertisement

